Nls pharmaceutics to participate in the canaccord genuity 41st annual growth conference

Stans, switzerland / accesswire / august 5, 2021 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that alex zwyer, chief executive officer and co-founder, is scheduled to present at the canaccord genuity 41st annual growth conference being held virtually august 10-12, 2021.
NLSP Ratings Summary
NLSP Quant Ranking